• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

晚期癌症患者复发性恶性腹水的腹腔内类固醇治疗：病例系列

Intraperitoneal Steroid Therapy for Recurrent Malignant Ascites in Advanced Cancer Patients: A Case Series.

作者信息

Islam Nashid, Biswas Jheelam, Sarker Shima Rani, Khanam Salma Ahsan

机构信息

Palliative Care Unit Bangladesh Cancer Society Hospital and Welfare Home Dhaka Bangladesh.

Intensive Care Unit National Institute of Cancer Research & Hospital Dhaka Bangladesh.

出版信息

Clin Case Rep. 2024 Dec 26;13(1):e70024. doi: 10.1002/ccr3.70024. eCollection 2025 Jan.

DOI:10.1002/ccr3.70024
PMID:39735790
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11671235/
Abstract

Intraperitoneal administration of depot corticosteroids following an initial paracentesis reduces ascitic fluid formation and extends the interval between subsequent paracentesis sessions. This approach may effectively manage recurrent malignant ascites and enhance patients' quality of life.

摘要

在首次腹腔穿刺术后腹腔内给予长效皮质类固醇可减少腹水形成，并延长后续腹腔穿刺术之间的间隔时间。这种方法可有效管理复发性恶性腹水并提高患者的生活质量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3693/11671235/b26ce0c0932e/CCR3-13-e70024-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3693/11671235/8ccd42482497/CCR3-13-e70024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3693/11671235/cd5a7878bc4e/CCR3-13-e70024-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3693/11671235/b26ce0c0932e/CCR3-13-e70024-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3693/11671235/8ccd42482497/CCR3-13-e70024-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3693/11671235/cd5a7878bc4e/CCR3-13-e70024-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3693/11671235/b26ce0c0932e/CCR3-13-e70024-g003.jpg

相似文献

1
Intraperitoneal Steroid Therapy for Recurrent Malignant Ascites in Advanced Cancer Patients: A Case Series.晚期癌症患者复发性恶性腹水的腹腔内类固醇治疗：病例系列
Clin Case Rep. 2024 Dec 26;13(1):e70024. doi: 10.1002/ccr3.70024. eCollection 2025 Jan.
2
A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites.曲安奈德己酸酯治疗复发性恶性症状性腹水的II期试验。
J Pain Symptom Manage. 2000 Mar;19(3):193-9. doi: 10.1016/s0885-3924(00)00106-8.
3
REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.REZOLVE（ANZGOG-1101）：一项腹腔内贝伐珠单抗治疗化疗耐药上皮性卵巢癌伴症状性腹水的 2 期临床试验。
Gynecol Oncol. 2021 May;161(2):374-381. doi: 10.1016/j.ygyno.2021.02.002. Epub 2021 Feb 23.
4
Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer.卵巢癌有症状性腹水姑息治疗中全腹腔穿刺术的腹腔内压力及临床参数
Gynecol Oncol. 1998 Dec;71(3):381-5. doi: 10.1006/gyno.1998.5215.
5
Central Venous Catheter as Peritoneal Indwelling Catheter for the Management of Recurrent Malignant Ascites: A Case Series.中心静脉导管作为腹腔留置导管用于复发性恶性腹水的治疗：病例系列
Indian J Palliat Care. 2019 Jan-Mar;25(1):57-60. doi: 10.4103/IJPC.IJPC_145_18.
6
Pilot study of intraperitoneal administration of triamcinolone acetonide for cancerous ascites in patients with end-stage gynecological cancer.
Int J Gynecol Cancer. 2014 Jul;24(6):1093-7. doi: 10.1097/IGC.0000000000000191.
7
A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.一项针对复发性卵巢癌有症状腹水患者的随机试验：腹腔穿刺术加腹腔内注射肿瘤坏死因子-α与单纯腹腔穿刺术的比较
Gynecol Oncol. 1997 Jan;64(1):80-7. doi: 10.1006/gyno.1996.4529.
8
Intraperitoneal bevacizumab for control of malignant ascites due to advanced-stage gastrointestinal cancers: A multicentre double-blind, placebo-controlled phase II study - AIO SUP-0108.腹腔内贝伐珠单抗治疗晚期胃肠道癌所致恶性腹水：多中心、双盲、安慰剂对照 II 期研究 - AIO SUP-0108。
Eur J Cancer. 2016 Aug;63:127-34. doi: 10.1016/j.ejca.2016.05.004. Epub 2016 Jun 15.
9
Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.浓缩腹水再回输治疗恶性腹水的疗效和安全性：概念验证研究。
Support Care Cancer. 2018 May;26(5):1489-1497. doi: 10.1007/s00520-017-3980-5. Epub 2017 Nov 22.
10
Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites.一项前瞻性研究，比较人血白蛋白与在肝硬化合并顽固性腹水患者进行完全腹腔穿刺放液后回输超滤后的腹水。
Z Gastroenterol. 2001 Jan;39(1):5-10. doi: 10.1055/s-2001-10707.

引用本文的文献

1
Intrapleural Steroid Therapy for Recurrent Malignant Pleural Effusion: A Case Report.胸腔内注射类固醇治疗复发性恶性胸腔积液：一例报告
Clin Case Rep. 2025 Sep 4;13(9):e70827. doi: 10.1002/ccr3.70827. eCollection 2025 Sep.

本文引用的文献

1
A survey of practice in management of malignancy-related ascites in Japan.日本恶性肿瘤相关性腹水管理实践调查。
PLoS One. 2019 Aug 9;14(8):e0220869. doi: 10.1371/journal.pone.0220869. eCollection 2019.
2
Effectiveness of intraperitoneal or intrapleural administration of triamcinolone acetonide for the control of malignant ascites and pleural effusion (Kansai Clinical Oncology Group-G1102 study).曲安奈德腹腔内或胸腔内给药控制恶性腹水和胸腔积液的有效性（关西临床肿瘤学组-G1102研究）
J Cancer Res Ther. 2017 Jul-Sep;13(3):446-450. doi: 10.4103/0973-1482.176426.
3
Diagnostic and prognostic value of SHOX2 and SEPT9 DNA methylation and cytology in benign, paramalignant, and malignant ascites.
SHOX2和SEPT9 DNA甲基化及细胞学检查在良性、准恶性和恶性腹水中的诊断及预后价值
Clin Epigenetics. 2016 Mar 1;8:24. doi: 10.1186/s13148-016-0192-7. eCollection 2016.
4
Pilot study of intraperitoneal administration of triamcinolone acetonide for cancerous ascites in patients with end-stage gynecological cancer.
Int J Gynecol Cancer. 2014 Jul;24(6):1093-7. doi: 10.1097/IGC.0000000000000191.
5
A pilot study of long-acting octreotide for symptomatic malignant ascites.长效奥曲肽治疗有症状恶性腹水的初步研究。
Oncology. 2012;82(6):315-20. doi: 10.1159/000337246. Epub 2012 May 10.
6
The use of intraperitoneal triamcinolone acetonide for the management of recurrent malignant ascites in a patient with non-Hodgkin's lymphoma.腹腔内注射曲安奈德用于治疗非霍奇金淋巴瘤患者复发性恶性腹水
J Pain Symptom Manage. 2008 Nov;36(5):e4-5. doi: 10.1016/j.jpainsymman.2008.07.002. Epub 2008 Sep 11.
7
A phase II trial of triamcinolone hexacetanide for symptomatic recurrent malignant ascites.曲安奈德己酸酯治疗复发性恶性症状性腹水的II期试验。
J Pain Symptom Manage. 2000 Mar;19(3):193-9. doi: 10.1016/s0885-3924(00)00106-8.
8
Contact allergens and sodium lauryl sulphate upregulate vascular endothelial growth factor in normal keratinocytes.
Br J Dermatol. 1997 Oct;137(4):540-4. doi: 10.1111/j.1365-2133.1997.tb03783.x.
9
Induction of vascular endothelial growth factor by platelet-activating factor and platelet-derived growth factor is downregulated by corticosteroids.血小板活化因子和血小板衍生生长因子对血管内皮生长因子的诱导作用会被皮质类固醇下调。
Am J Respir Cell Mol Biol. 1997 Apr;16(4):398-406. doi: 10.1165/ajrcmb.16.4.9115750.
10
Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.豚鼠和人类肿瘤及炎性渗出液中的血管通透性因子（血管内皮生长因子）
Cancer Res. 1993 Jun 15;53(12):2912-8.